Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;10(4):211.
doi: 10.1186/bcr2112. Epub 2008 Jul 24.

Molecular targeted therapies for breast cancer treatment

Claus M Schlotter  1 , Ulf Vogt, Heike Allgayer, Burkhard Brandt
Affiliations
Review

Molecular targeted therapies for breast cancer treatment

Claus M Schlotter et al. Breast Cancer Res. 2008.

Abstract

Targeting the oestrogen receptor, HER2 (human epidermal growth factor receptor 2) and vascular endothelial growth factor has markedly improved breast cancer therapy. New targeted therapeutic approaches to induction of apoptosis or inhibition of anti-apoptosis, cell cycle progression, signal transduction and angiogenesis are described. The molecular pathways and their inhibitory or repair mechanisms are discussed in the preclinical and clinical settings.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cell signalling pathways: targets for breast cancer treatment. EGFR, epidermal growth factor receptor; GPCR, G-protein-coupled receptors; HER, human epidermal growth factor receptor; IKK, inhibitor of NF-κB kinase; mTOR, mammalian target of rapamycin; NF-κB, nuclear factor-κB; TRAIL, tumour necrosis factor-related apoptosis inducing ligand; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
See this image and copyright information in PMC

References

    1. Lin A, Rugo HS. The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007;8:47–60. doi: 10.1007/s11864-007-0008-2. - DOI - PubMed
    1. Vogt U, Schlotter CM, Allgayer H. Biologicrational therapeutic strategies: targeted therapies. In: Schlotter CM, Bonk U, Brandt B Bremen, editor. Individualized concepts of neo-adjuvant and adjuvant therapy of breast cancer – gene and gene expression [in German] London, Boston: UNI-MED Verlag; 2007.
    1. Slamon D, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. doi: 10.1056/NEJM200103153441101. - DOI - PubMed
    1. Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005;353:1734–1736. doi: 10.1056/NEJMe058196. - DOI - PubMed
    1. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–2676. doi: 10.1056/NEJMoa072113. - DOI - PubMed